There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug Administration approved semaglutide for use as a weight-loss drug in 2021.

A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

The study found a sharp increase in the share of patients who received GLP-1 RAs during the study period, with GLP-1 RA use increasing 132.6% from the last six months of 2022 to the last six ...

A line graph published along with study shows the incidence of people newly being prescribed GLP-1s takes a steep upward charge after 2020. Semaglutide was approved by the FDA for weight loss in 2021.

Many of the GLP-1 patients in their study also never reached the maximum dose. Chhabra also suspects that many people in the real world aren’t getting the supportive care and follow-up they ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4% in 2022. As a result, annual spending jumped from $1.6 billion to $5. ...

While GLP-1 use may be temporary, the mindset shift is likely long-term. Consumers who start their weight loss journey with these medications are developing new habits and looking for products to ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Sai Lomte, Tarun. (2025, May 14). GLP-1 weight loss drugs leave users low on key nutrients, study ...

In a matched group of more than 170,000 adults, those treated with GLP-1 agonists had a lower risk of developing an obesity-related cancer over a median follow-up of about 4 years when compared ...

Overall, 188 people returned for at least one follow-up visit. And people who drank alcohol reported drinking less on average after starting a GLP-1 drug.